Cohance Lifesciences
987.50
-2.35(-0.24%)
Market Cap₹37,778.51 Cr
PE Ratio107.70
IndustryHealthcare
Company Performance:
1D-0.24%
1M+4.88%
6M-14.68%
1Y-17.03%
5Y+184.38%
View Company Insightsright
More news about Cohance Lifesciences
20Jun 25
Cohance Lifesciences Divests CR Bio Unit to Chromo Labs for Rs 16 Crore
Cohance Lifesciences has sold its non-core CR Bio unit to Chromo Labs for Rs 16 crore. This strategic divestment is aimed at streamlining operations and focusing on the company's core Contract Development and Manufacturing Organization (CDMO) business. The move is expected to allow Cohance to concentrate resources, improve operational efficiency, and strengthen its position in the CDMO sector.
07May 25
Suven Pharma Set to Rebrand as Cohance Lifesciences Following Government Approval
Suven Pharmaceuticals Limited has received governmental approval to change its name to Cohance Lifesciences. This rebranding initiative marks a significant corporate development for the Indian pharmaceutical company. While specific reasons for the name change were not disclosed, it likely reflects a strategic shift in the company's focus or aspirations within the life sciences sector. The transition may involve updates to corporate materials and legal documents, but is not expected to affect the company's ownership structure or share value.
25Apr 25
Suven Pharma Secures Final Approval for Merger with Cohance Lifesciences
Suven Pharmaceuticals Limited has received final approval for its merger with Cohance Lifesciences, effective from May 1, 2025. The merged entity will operate as Cohance Lifesciences. Shareholders of Cohance Lifesciences will receive 11 equity shares of Suven Pharma for every 295 shares held, with May 8, 2025 set as the record date. The merger has obtained all necessary regulatory clearances, including NCLT approval and foreign investment clearance.
23Apr 25
Suven Pharma Secures Government Approval for Increased Foreign Investment Post-Merger
Suven Pharmaceuticals Limited has obtained approval from the Department of Pharmaceuticals, allowing for potential foreign investment above 74% following its merger with Cohance Lifesciences Limited. This approval, granted on April 22, 2025, is a crucial step in the merger process, which was initially approved by the Board on February 29, 2024. The National Company Law Tribunal sanctioned the Scheme of Amalgamation on March 27, 2025, following shareholder approval on November 28, 2024. The merger's Effective Date will be announced once all conditions are met.
28Mar 25
NCLT Approves Merger of Cohance Lifesciences with Suven Pharma
The National Company Law Tribunal (NCLT) has approved the merger between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited. The merger will be effective from the first day of the month following the fulfillment of all conditions. Shareholders of Cohance will receive 11 shares of Suven for every 295 shares held. The combined entity aims to become a leading diversified CDMO in India, with expanded capabilities, an enhanced customer base, and access to multiple FDA-audited GMP facilities. The merger is expected to bring synergy benefits, accelerating growth and improving margins.
Cohance Lifesciences
987.50
-2.35
(-0.24%)
1 Year Returns:-17.03%
Industry Peers
Sun Pharmaceutical
1,602.80
(+0.59%)
Divis Laboratories
6,007.00
(-0.41%)
Cipla
1,558.80
(-0.32%)
Torrent Pharmaceuticals
3,582.70
(-0.25%)
Dr Reddys Laboratories
1,293.50
(-0.82%)
Mankind Pharma
2,590.10
(-0.71%)
Zydus Life Science
1,038.15
(-0.14%)
Lupin
1,978.90
(-0.04%)
Abbott
31,085.00
(-0.54%)
Alkem Laboratories
5,378.50
(+1.09%)